Anterior gradient 2 (AGR2): Blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype

Prostate

Volumn 73, Issue 3, 2013, Pages 306-315

  Kani, Kian ^a   Malihi, Paymaneh D ^a   Jiang, Yuqiu ^b   Wang, Haiying ^b   Wang, Yixin ^b   Ruderman, Daniel L ^a   Agus, David B ^a   Mallick, Parag ^a,c   Gross, Mitchell E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b JOHNSON AND JOHNSON   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

AGR2; biomarker; metastasis; neuroendocrine prostate cancer

Indexed keywords

ANTERIOR GRADIENT 2 PROTEIN; ANTIANDROGEN; MESSENGER RNA; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLOOD ANALYSIS; BONE METASTASIS; CANCER CELL CULTURE; CASTRATION RESISTANT PROSTATE CANCER; CASTRATION SENSITIVE PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR CELL;

ADENOCARCINOMA; AGED; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CHROMOGRANIN A; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; NEUROENDOCRINE TUMORS; PHENOTYPE; PHOSPHOPYRUVATE HYDRATASE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEINS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84872804120     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22569     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Zhang JS, Gong A, Cheville JC, Smith DI, Young CY,. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer 2005; 43 (3): 249-259.
3. Persson S, Rosenquist M, Knoblach B, Khosravi-Far R, Sommarin M, Michalak M,. Diversity of the protein disulfide isomerase family: Identification of breast tumor induced Hag2 and Hag3 as novel members of the protein family. Mol Phylogenet Evol 2005; 36 (3): 734-740.
4. Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R,. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res 2005; 65 (9): 3796-3805.
5. Wang Z, Hao Y, Lowe AW,. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 2008; 68 (2): 492-497.
6. Ramachandran V, Arumugam T, Wang H, Logsdon CD,. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res 2008; 68 (19): 7811-7818.
7. Brychtova V, Vojtesek B, Hrstka R,. Anterior gradient 2: A novel player in tumor cell biology. Cancer Lett 2011; 304 (1): 1-7.
8. Zhang Y, Ali TZ, Zhou H, D'Souza DR, Lu Y, Jaffe J, Liu Z, Passaniti A, Hamburger AW,. ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer. Cancer Res 2010; 70 (1): 240-248.
9. Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Kaplan W, Breit SN, Sutherland RL, Henshall SM, Horvath LG,. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res 2009; 69 (19): 7696-7703.
10. Bu H, Bormann S, Schafer G, Horninger W, Massoner P, Neeb A, Lakshmanan VK, Maddalo D, Nestl A, Sultmann H, Cato AC, Klocker H,. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate 2011; 71 (6): 575-587.
11. Zhang Y, Forootan SS, Liu D, Barraclough R, Foster CS, Rudland PS, Ke Y,. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis 2007; 10 (3): 293-300.
12. Maresh EL, Mah V, Alavi M, Horvath S, Bagryanova L, Liebeskind ES, Knutzen LA, Zhou Y, Chia D, Liu AY, Goodglick L,. Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC cancer 2010; 10: 680.
13. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ,. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 2004; 64 (24): 9209-9216.
14. Mocellin S, Keilholz U, Rossi CR, Nitti D,. Circulating tumor cells: The 'leukemic phase' of solid cancers. Trends Mol Med 2006; 12 (3): 130-139.
15. Pantel K, Brakenhoff RH,. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4 (6): 448-456.
16. Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME,. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 2010; 56 (9): 1492-1495.
17. O'Hara S, Moreno J, Zweitzig D, Gross S, Gomella L, Terstappen L,. Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin Chem 2004; 50 (5): 826-835.
18. Shaffer D, Leversha M, Danila D, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle G, Terstappen L, Lilja H, Heller G, Fleisher M, Scher H,. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13 (7): 2023-2029.
19. Clark J, Attard G, Jhavar S, Flohr P, Reid A, De-Bono J, Eeles R, Scardino P, Cuzick J, Fisher G, Parker MD, Foster CS, Berney D, Kovacs G, Cooper CS,. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 2008; 27 (14): 1993-2003.
20. Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG, Connelly MC, Terstappen LW, O'Hara SM,. Global gene expression profiling of circulating tumor cells. Cancer Res 2005; 65 (12): 4993-4997.
21. Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, Gratama JW, Sleijfer S, Foekens JA,. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat 2009; 118 (3): 455-468.
22. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van Galen A, de Weerd V, Kraan J, van der Spoel P, Ramirez-Moreno R, van Deurzen CH, Smid M, Yu JX, Jiang J, Wang Y, Gratama JW, Sleijfer S, Foekens JA, Martens JW,. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 2011; 17 (11): 3600-3618.
23. Edgell TA, Barraclough DL, Rajic A, Dhulia J, Lewis KJ, Armes JE, Barraclough R, Rudland PS, Rice GE, Autelitano DJ,. Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer. Clin Sci (Lond) 2010; 118 (12): 717-725.
24. Makawita S, Smith C, Batruch I, Zheng Y, Ruckert F, Grutzmann R, Pilarsky C, Gallinger S, Diamandis EP,. Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics 2011; 10 (10): M111 008599.
25. Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB, Mallick P,. Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. Mol Cancer Ther 2012; 11 (5): 1071-1081.
26. Belsley DA, Kuh E, Welsch RE,. Regression diagnostics: Identifying influential data and sources of collinearity. New York: John Wiley & Sons; 2004. 292 p.
27. Scher HI, Heller G,. Clinical states in prostate cancer: Toward a dynamic model of disease progression. Urology 2000; 55 (3): 323-327.
28. Matei DV, Renne G, Pimentel M, Sandri MT, Zorzino L, Botteri E, De Cicco C, Musi G, Brescia A, Mazzoleni F, Valeria T, Detti S, de Cobelli O,. Neuroendocrine differentiation in castration-resistant prostate cancer: A systematic diagnostic attempt. Clin Genitourin Cancer 2012; 10 (3): 164-173.
29. Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LWMM, Allard WJ, Bilbee M, Cheng JD, Hoffman JP, Lewis NL, Pellegrino A, Rogatko A, Sigurdson E, Wang H, Watson JC, Weiner LM, Meropol NJ,. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6 (2): 125-132.
30. Balk SP, Ko YJ, Bubley GJ,. Biology of prostate-specific antigen. J Clin Oncol 2003; 21 (2): 383-391.
31. Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, Joly F, Oudard S, Deplanque G, Zanetta S, Fargeot P, Priou F, Droz JP, Culine S,. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: Results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011; 22 (11): 2476-2481.
32. Sobel RE, Sadar MD,. Cell lines used in prostate cancer research: A compendium of old and new lines-part 1. J Urol 2005; 173 (2): 342-359.
33. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG,. CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996; 56 (13): 3042-3046.
34. Sramkoski RM, Pretlow TG II, Giaconia JM, Pretlowv TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW,. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999; 35 (7): 403-409.
35. Kozlov G, Maattanen P, Thomas DY, Gehring K,. A structural overview of the PDI family of proteins. FEBS J 2010; 277 (19): 3924-3936.
36. Huber M, Bahr I, Kratzschmar JR, Becker A, Muller EC, Donner P, Pohlenz HD, Schneider MR, Sommer A,. Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r. Mol Cell Proteomics 2004; 3 (1): 43-55.
37. Ather MH, Abbas F,. Prognostic significance of neuroendocrine differentiation in prostate cancer. Eur Urol 2000; 38 (5): 535-542.
38. Aparicio A, Harzstark AL, Lin E, Corn PG, Araujo JC, Tu S, Pagliaro LC, Millikan RE, Arap W, Kim J, Ryan CJ, Zurita AJ, Tannir NM, Lin AM, Small EJ, Mathew P, Jones DM, Troncoso P, Thall PF, Logothetis C,. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) andsalvage etoposide and cisplatin (EP). J Clin Oncol 2011; (29 Suppl.) abstr. 4666.
39. Angelsen A, Syversen U, Stridsberg M, Haugen OA, Mjolnerod OK, Waldum HL,. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 1997; 31 (2): 110-117.